-
Covid-19 Protection Framework: Our offices are open. Visitors should sign-in, wear a mask, and follow social distance guidelines. Our contact details
APP204349
Application overview
- Application code:
- APP204349
- Application type:
- GM Development
- Applicant:
- Malaghan Institute of Medical Research
- Applicant postal address:
- PO Box 7060, Newtown, Wellington, 6242, New Zealand
- Application state:
- Decided
- Application decision:
- Approved with Controls
- Application purpose:
- To develop genetically modified human cells for the packaging and testing of 3rd generation self-inactivating lentiviral vectors, to be used to genetically modify human T cells for the expression of genes that regulate the activity of human immune cells.
- Decision notified date:
- 20 December 2021
- IBSC Reference:
Application documents
- APP204349 Application.pdf(PDF, 1.2 MB)
- APP204349 Approval.pdf(PDF, 175 KB)
- APP204349 Decision (May only be used by the Approval-holder).pdf(PDF, 296 KB)
- APP204349 Memorandum exercising EPA discretion not to notify.pdf(PDF, 190 KB)
- APP204349 Staff Advice Report to Decision-making Committee.pdf(PDF, 699 KB)
Substances or organisms in application
- Name:
- Human commercial somatic cell lines and primary immune cells
- Decision:
- Approved with Controls
- Synonyms:
- Approval number:
- GMD102750
- Trade names:
- Homo sapiens (animal, mammal, GM, development, cell line, human)
- Approval status:
- Approval expiry date:
- Application superceded by: